Valuation: Kamada Ltd.

Market Cap 1.3B 0 433M 378M 348M 324M 615M 41.22B 624M 4.18B 1.62B 20.26B 1.63B 1.59B 69.83B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.3B 0 433M 378M 348M 324M 615M 41.22B 624M 4.18B 1.62B 20.26B 1.63B 1.59B 69.83B EV / Sales 2026 *
2.22x
EV / Sales 2027 * 2.02x
Free-Float
54.51%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 57 2015-06-30
Director of Finance/CFO 55 2017-12-30
Chief Operating Officer 53 2016-10-31
Director TitleAgeSince
Director/Board Member 75 1990-12-12
Chairman 77 2013-03-06
Chairman 55 2020-08-11
Change 5-day change 1-year change 3-year change Capi.($)
-0.53%-1.04% - - 435M
+4.73%+3.38%+19.53%-8.89% 66.56B
-1.93%+0.39%+58.62%+226.33% 57.64B
+1.07%+42.10%+42.10%+42.10% 42.24B
+3.45%+6.04%-49.46%-55.91% 39.09B
+3.04%+0.04%+62.66%-24.29% 31.91B
+10.01%+18.57%+161.59%-34.48% 31.65B
+2.68%+2.73%+70.72%+88.24% 23.35B
+2.87%+16.83%+3.78%+192.67% 18.92B
-0.13%+2.75%+67.48%+130.07% 17.17B
Average +2.53%+7.50%+48.56%+61.76% 36.5B
Weighted average by Cap. +2.77%+6.28%+44.19%+55.15%

Financials

2026 *2027 *
Net sales 585M 0 195M 171M 157M 146M 277M 18.57B 281M 1.88B 731M 9.13B 732M 716M 31.46B 642M 0 214M 187M 172M 160M 304M 20.39B 309M 2.07B 803M 10.02B 804M 786M 34.53B
Net income 72.01M 0 24.02M 21M 19.3M 17.99M 34.12M 2.29B 34.64M 232M 90.07M 1.12B 90.17M 88.23M 3.87B 104M 0 34.57M 30.22M 27.78M 25.89M 49.11M 3.29B 49.85M 333M 130M 1.62B 130M 127M 5.58B
Net Debt - -
Logo Kamada Ltd.
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Employees
-
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-